About Tourmaline Bio Inc.

Tourmaline Bio Inc., founded with a mission to develop transformative treatments for autoimmune and inflammatory diseases, has built a pipeline targeting significant unmet medical needs in immunology. The company focuses on novel mechanisms of action that could provide superior efficacy and safety. TRML stock price reflects investor interest in the company's immunology focus and innovative therapeutic approach.

Led by an experienced management team with backgrounds in immunology and drug development, Tourmaline Bio has assembled scientific and clinical expertise to advance its innovative platform. The leadership team combines deep understanding of immune system biology with proven capabilities in translating scientific insights into clinical candidates. Management's strategic focus on novel immunomodulatory approaches has been important for building a differentiated development strategy and influencing TRML stock price potential.

Tourmaline Bio operates by developing therapies that modulate immune system function to treat autoimmune and inflammatory diseases using novel mechanisms that could provide improved efficacy and reduced side effects compared to current treatments. The company's pipeline focuses on conditions with significant unmet medical needs and large patient populations. With autoimmune diseases affecting millions of patients globally, limited effectiveness of current therapies creating opportunities for innovation, and Tourmaline Bio's focus on novel immunomodulatory approaches, TRML offers investors exposure to innovative immunology therapeutics with potential for meaningful patient impact and commercial success in large and underserved markets.